Medincell announces that it has received an additional grant of up to six million dollars over three years from the global health agency Unitaid, to finance the phase 1 clinical trial of the injectable long-acting treatment mdc-STM.

If proven safe, effective and well-tolerated, it could have a significant impact on malaria transmission in vulnerable populations living in the most affected areas", says the biopharmaceutical company.

Malaria remains endemic in 85 countries representing 50% of the world's population. According to WHO estimates, 249 million people were infected worldwide in 2022, 94% of them in Africa, resulting in 580,000 deaths in this region.

Copyright (c) 2024 CercleFinance.com. All rights reserved.